Study of Menin Inhibitor Maintenance Therapy After Allogeneic Stem Cell Transplant in Acute Leukemia Patients

What this Trial Is About

This research aims to evaluate the effectiveness and safety of menin inhibitor maintenance therapy in patients with acute leukemia who have undergone allogeneic hematopoietic stem cell transplantation allo-HSCT. Patients with high-risk subtypes, such as those with KMT2A rearrangements, face high relapse rates after transplantation. The study focuses on understanding how menin inhibitors, including drugs like Revumenib, BN104, Ziftomenib, and HMPL-506, may impact relapse-free survival and overall outcomes in a real-world setting. Eligible patients will receive menin inhibitor maintenance therapy as part of their routine clinical care, with the choice of specific drug, timing, dosage, and treatment duration decided by their doctors. The study does not impose extra interventions beyond usual clinical management. After starting maintenance therapy, patients will be monitored during each treatment cycle, and after treatment ends, survival follow-up visits will occur every three cycles to track long-term outcomes. Participants will be regularly assessed for treatment effectiveness and safety throughout the therapy and follow-up periods. Key outcomes include the two-year relapse-free survival rate, overall survival, event-free survival, relapse incidence, and treatment-related safety measures such as graft-versus-host disease. The study will continue until December 2029, providing comprehensive data on menin inhibitor use in post-transplant maintenance therapy for acute leukemia.

A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT